Technological and Patient-tailored Innovations for Maximizing Effectiveness of Cardiac Arrest Resuscitation

NCT ID: NCT06538155

Last Updated: 2025-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-27

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Out-of-hospital cardiac arrest (OHCA) affects 275,000 people in Europe every year. In Italy alone, 50,000 people experience OHCA annually, with only 9% surviving. Half of the survivors suffer severe brain damage. Immediate CPR and defibrillation by bystanders before the ambulance arrives can save lives, but often, CPR starts only when the ambulance gets there. Additionally, half of all OHCAs occur when the person is alone, causing delays in recognizing the emergency, calling for help, and starting lifesaving actions. Effective chest compressions and defibrillation are crucial but are often not done correctly or are not customized for each patient. Current guidelines recommend the same approach for everyone, which doesn't consider individual needs.

To tackle these issues, we plan to develop artificial intelligence (AI) algorithms, smartphone apps, and new devices. Our main goal is to create tools and technologies to improve the recognition of OHCA and provide timely and effective interventions, ultimately reducing the impact of OHCA and improving survival rates.

First, we aim to create an AI algorithm that can predict major cardiovascular events like heart attacks or cardiac arrests minutes, hours, or days before they happen. We will collect data from wearable devices to train and validate this algorithm, helping us identify individuals at risk. By alerting these individuals, they can seek emergency care and receive treatment before a cardiac arrest occurs. We will also work on recognizing OHCA cases from surveillance camera footage when they happen to people who are alone.

Second, to increase the rate of CPR and defibrillation before ambulances arrive, we will develop a smartphone app that geolocates and alerts nearby citizens to act as first responders. The app will guide them on how to quickly find a defibrillator and use it.

Third, to find the best spots on the chest for compressions and defibrillation, we will study chest scans from CTs and echocardiograms in both elective patients and cardiac arrest victims. This will help us understand the effects of compressing different heart structures and develop a sensor to determine the optimal positions for compressions and defibrillator pads.

Our multidisciplinary team of clinicians, researchers, and engineers will conduct experimental, simulation, and observational studies to develop these technologies, evaluate their potential for patents, design a plan for their use, and test their effectiveness in preventing and recognizing OHCA. We believe that by improving each step in the chain of survival-preventing cardiac events, early recognition, timely CPR and defibrillation, and high-quality advanced resuscitation-we can significantly improve treatment times and reduce the global death and disability rates caused by OHCA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Out-of-hospital cardiac arrest (OHCA) annually affects 275000 individuals in Europe. In Italy alone, 50000 persons suffer from OHCA each year and only 9% survives1. Half of the survivors are left with severe brain damage. Prompt cardiopulmonary resuscitation (CPR) and defibrillation before ambulance arrival by bystanders can improve outcomes. However, in many cases, CPR only starts when the ambulance arrives. Additionally, half of all OHCAs occur in isolation, meaning that recognition, emergency calls, and lifesaving maneuvers are delayed. Chest compressions and defibrillation are critical for survival, but they are frequently inadequate or not patient-tailored. Current CPR guidelines recommend a uniform approach to chest compressions and defibrillation for all patients, which fails to account for individual differences. To address these unmet medical needs, we will develop artificial intelligence algorithms, smartphone apps, and novel devices. Starting with proof-of-concept approaches that we have already conceived, we will work to improve recognition of OHCA and provide timely and effective interventions. Our goal is to create tools and technologies that can help reduce the burden of OHCA and improve outcomes.

First, we aim to develop an artificial intelligence algorithm that can predict (minutes, hours, or days in advance) major cardiovascular events, such as myocardial infarction or cardiac arrest. To achieve this, we will collect biosignals recorded by wearables to train and validate the algorithm to identify individuals who are at risk of a major cardiovascular event. Alerted individuals will seek emergency medical care and receive treatments before a cardiac arrest occurs. We also aim to recognize OHCAs that occur in isolation from videos of surveillance cameras.

Second, to increase the rate of CPR and defibrillation provided before ambulance arrival, we will develop a smartphone app that will geolocate and alert nearby citizens to act as first responders. The app will also provide guidance on quickly retrieving a defibrillator.

Third, to determine the optimal compressions and defibrillation position on the chest, we will acquire scans of chest computer tomography and transesophageal echocardiography in elective patients and in victims of cardiac arrest. This will allow to determine optimal compression and defibrillator pads position, understanding the effects on outcomes of different cardiac structures compressed, and developing a modern sensor to estimate the optimal compression and defibrillator pads position on the chest.

Through experimental, simulation and observational studies and a multidisciplinary team of clinicians, researchers and engineers, we will develop the proof-of-concept of such technologies, evaluate their patentability, design an exploitation plan, and test efficacy in preventing and anticipating recognition of OHCA, reducing time to CPR and defibrillation, and offering patient-tailored CPR and defibrillation. Our underlying hypothesis is that developing novel methods and technologies to enhance each link in the chain of survival (preventative measures, early recognition, timely initiation of CPR and defibrillation, and high-quality advanced resuscitation) will significantly anticipate lifesaving treatments and reduce the global mortality and disability caused by OHCA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Out-Of-Hospital Cardiac Arrest Cardiac Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wearable device users

Healthy volunteers (every adult individual with no history of cardiovascular events willing to contribute to the project) and patients who experienced major cardiovascular events (i.e., myocardial infarction or cardiac arrest). Both groups must have worn a wearable device or used a smartphone able to collect healthcare data and biosignals.

Wearable device

Intervention Type DEVICE

Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked

Patients with cardiac arrest

Adults resuscitated after cardiac arrest or during ongoing cardiopulmonary resuscitation (CPR).

Cardiopulmonary resuscitation

Intervention Type OTHER

Cardiopulmonary resuscitation

CT scan, TEE exam, or chest X ray

Intervention Type OTHER

Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray

Patients who received a CT scan

Adults who received a chest CT scan for any reasons.

CT scan, TEE exam, or chest X ray

Intervention Type OTHER

Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wearable device

Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked

Intervention Type DEVICE

Cardiopulmonary resuscitation

Cardiopulmonary resuscitation

Intervention Type OTHER

CT scan, TEE exam, or chest X ray

Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-70 years;
* Being a healthy volunteer (i.e., an individual with no history of cardiovascular events willing to contribute to the project) or a patient (survivors and non-survivors) who experienced major cardiovascular events (i.e., myocardial infarction or cardiac arrest);
* Users of a smartwatch or smartphone that continuously and automatically collect health data;
* Informed consent.


* Adults (≥ 18 years);
* Patients suffering a non-traumatic cardiac arrest treated with chest compressions (both survivors and non-survivors);
* Received a TEE, chest x-ray, or chest CT scan as the standard clinical assessment following cardiac arrest;
* Informed consent.


* Adults (≥ 18 years);
* Received a chest CT scan for any reasons;
* Informed consent.

Exclusion Criteria

* Impossibility to access/export data;
* User did not wear the wearable device for periods longer than 24 hours;
* User did not wear the wearable device in the 4 weeks preceding the event.

AIM 1.2 CARDIAC ARREST DETECTION FROM VIDEOS No patient involved.

AIM 2: TECHNOLOGIES TO INCREASE CPR AND DEFIBRILLATION USE BEFORE AMBULANCE ARRIVAL No patient involved.

AIM 3: PATIENT-TAILORED RESUSCITATION AIM 3.1: CLINICAL STUDY IN PATIENTS WHO RECEIVED CPR


\- Patients with severe thorax/mediastinal deformity.

AIM 3.2 CLINICAL STUDY IN PATIENTS WHO RECEIVED A CHEST CT SCAN


\- Patients with severe thorax/mediastinal deformity.

AIM 3.3 MACHINE LEARNING (ML) ALGORITHM No patient involved.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS Ospedale San Raffaele

OTHER

Sponsor Role collaborator

Politecnico di Milano

OTHER

Sponsor Role collaborator

Azienda Ospedaliera Universitaria "Luigi Vanvitelli" (AOV)

UNKNOWN

Sponsor Role collaborator

Azienda Ospedaliera Universitaria Federico II (AOU Federico II)

UNKNOWN

Sponsor Role collaborator

Università Vita-Salute San Raffaele

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giovanni Landoni

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alberto Zangrillo, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Ospedale San Raffaele

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS Ospedale San Raffaele

Milan, , Italy

Site Status RECRUITING

AOU Policlinico Federico II

Napoli, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria Vanvitelli

Napoli, , Italy

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Giovanni Landoni, MD

Role: CONTACT

+390226436151

Tommaso Scquizzato, MD

Role: CONTACT

+390226436151

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tommaso Squizzato, MD

Role: primary

0226438296 ext. +39

Maria Caterina Pace, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PNRR-POC-2023-123771

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

TIME-CARE 264-2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Automated Real-time Feedback on CPR Study
NCT00539539 COMPLETED PHASE2
SNPeCPR In Cardiac Arrest REsuscitation
NCT02225561 TERMINATED PHASE3